Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

T790M mutation

AstraZeneca AZ

AZ’s US-based COVID-19 vaccine trial could restart this week

Sources briefed on the matter disclosed possible timeline to Reuters

- PMLiVE

BMS’ Opdivo is first immunotherapy to score phase 3 win in pre-surgery NSCLC

Checkpoint inhibitor plus chemo meets first primary endpoint in late-stage trial

- PMLiVE

EMA begins rolling review of AZ’s COVID-19 vaccine candidate

Agency has started evaluating data from non-clinical laboratory studies

AstraZeneca AZ

Japan resumes AZ’s COVID-19 vaccine trial, but US study remains on hold

Trials have also resumed in the UK, India, South Africa and Brazil

AstraZeneca AZ

EU will shoulder certain liability costs in AZ COVID-19 vaccine deal

Low-cost deal will see the EU assume responsibility for side-effect claims

- PMLiVE

Keytruda doubles five-year survival rate in NSCLC

Merck reveals long-term efficacy data for blockbuster immunotherapy

- PMLiVE

Janssen’s EGFR-targeting treatment regimen shows early benefit in lung cancer

Positive interim results presented at 2020 ESMO virtual congress

- PMLiVE

AZ/Merck’s Lynparza improves survival in certain prostate cancers

New data released at ESMO 2020 virtual congress shows drug cuts the risk of death

AstraZeneca AZ

AZ’s Tagrisso cuts risk of EGFR-positive NSCLC spreading to the brain

Results showing EGFR-inhibitor improves outcomes in adjuvant setting released at ESMO 2020 virtual congress

AstraZeneca AZ

AZ pauses COVID-19 vaccine study after participant falls ill

Serious adverse event puts clinical programme on hold

AstraZeneca AZ

AZ’s Farxiga cuts risk of death in chronic kidney disease

Detailed results revealed at the European Society of Cardiology virtual congress

AstraZeneca AZ

AZ scores FDA priority review for new Imfinzi fixed-dose regimen

Four-week dosing schedule offers new flexibility for patients

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links